talipexole has been researched along with (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dan, K; Furukawa, T; Kushiku, K; Mukai, M; Yamada, H; Yamada, K | 1 |
1 other study(ies) available for talipexole and (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride
| Article | Year |
|---|---|
The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia.
Topics: (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Animals; Azepines; Benzazepines; Dimethylphenylpiperazinium Iodide; Dogs; Dopamine Agonists; Female; Ganglia, Sympathetic; Heart Rate; Male; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride; Synaptic Transmission | 1996 |